A Phase 1 Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of SKB571 for Injection in Subjects With Advanced Solid Tumors
Latest Information Update: 21 Jan 2026
At a glance
- Drugs SKB 571 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Sichuan Kelun Pharmaceutical Research Institute; Sichuan Kelun-Biotech Biopharmaceutical
Most Recent Events
- 17 Nov 2025 Status changed from not yet recruiting to recruiting.
- 18 Dec 2024 New trial record